For patients struggling with persistent heel pain, chronic bursitis, or stubborn tendinitis, the conventional treatment cycle often feels like an endless loop: weeks of ice and rest, physical therapy plateaus, and repeated cortisone injections that only offer short-lived relief. When these conservative options stall, patients are frequently left wondering what steps remain before invasive surgery.

Now, national clinical guidelines provide a clear answer.

Co-authored by Dr. Bobby N. Koneru, MD, FASTRO, Chief Medical Officer and co-founder of JointGlow, a new Appropriate Use Criteria (AUC) consensus published in the American Journal of Clinical Oncology establishes formal expert consensus for using Low-Dose Radiotherapy (LDRT) to treat inflammatory periarticular disorders.

Commissioned by the American Radium Society (ARS), this comprehensive systematic review evaluates decades of clinical evidence across thousands of patients to provide physician-backed recommendations for common, treatment-resistant inflammatory conditions.

What the ARS Guidelines Conclude

Using rigorous consensus methodology, the expert multispecialty panel analyzed evidence covering conditions such as plantar fasciitis, bursitis, tendinitis, and enthesitis:

1. Proven Appropriate for Chronic Plantar Fasciitis

The guidelines affirm that LDRT is an appropriate second-line treatment for chronic plantar fasciitis that has not resolved with standard conservative measures. For patients who continue to experience sharp heel pain each morning despite orthotics, stretching, and injections, LDRT provides a non-invasive biological reset.

2. Clear Indications for Bursitis and Tendon Inflammation

The consensus panel determined that LDRT is an appropriate second-line treatment for other chronic periarticular disorders, such as persistent hip bursitis, shoulder bursitis, and elbow tendinitis, provided there are no full-thickness structural tears.

3. Defining the Ideal Window of Care

The guidelines emphasize patient selection: LDRT is recommended as a targeted second-line intervention when first-line therapies fail, serving as an effective bridge that helps patients resolve chronic inflammation without escalating to invasive surgery.

How LDRT Calms Inflammatory Pain at the Source

Unlike oral medications that circulate systemically or steroid shots that wash out over time, Low-Dose Radiotherapy delivers ultra-low energy directly to inflamed soft tissues:

  • Switches Immune Signaling: LDRT signals overactive white blood cells (macrophages) to shift from a destructive “attack” mode to an anti-inflammatory “repair” mode.
  • Reduces Tissue Irritation: Calms the microscopic chemical cascade that keeps bursa sacs swollen and tendons tender.
  • Preserves Structural Integrity: Unlike repeated cortisone shots, which can weaken tendon fibers and accelerate tissue degeneration, LDRT calms inflammation without damaging surrounding soft tissue.

Experience Evidence-Based Care at JointGlow

Under the clinical direction of physician pioneers like Dr. Koneru, JointGlow brings these national guidelines to everyday patient care:

  • Zero surgery: 100% non-invasive outpatient treatment.
  • Zero needles: No painful injections or aspirations.
  • Zero downtime: Brief sessions take about 10 minutes so that you can return to your normal routine immediately.
  • Covered by insurance: Medicare and most major private insurance plans cover LDRT.

Ready to Break Free From Chronic Inflammation?

If nagging heel, shoulder, elbow, or hip pain has kept you from walking, exercising, or sleeping comfortably, you don’t have to settle for temporary band-aids.

Schedule your consultation with JointGlow today to see whether Low-Dose Radiotherapy is the right next step in your recovery.